Literature DB >> 31559963

BPaL approved for multidrug-resistant tuberculosis.

Talha Burki.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31559963     DOI： 10.1016/S1473-3099(19)30489-X

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN： 1473-3099            Impact factor:   25.071


× No keyword cloud information.
  2 in total

1.  Budgetary impact of using BPaL for treating extensively drug-resistant tuberculosis.

Authors:  Christiaan Mulder; Stephan Rupert; Ery Setiawan; Elmira Mambetova; Patience Edo; Jhon Sugiharto; Sani Useni; Shelly Malhotra; Sarah Cook-Scalise; Imran Pambudi; Abdullaat Kadyrov; Adebola Lawanson; Susan van den Hof; Agnes Gebhard; Sandeep Juneja; Hojoon Sohn
Journal:  BMJ Glob Health       Date:  2022-01

2.  Integrative analysis of clinical health records, imaging and pathogen genomics identifies personalized predictors of disease prognosis in tuberculosis.

Authors:  Awanti Sambarey; Kirk Smith; Carolina Chung; Harkirat Singh Arora; Zhenhua Yang; Prachi Agarwal; Sriram Chandrasekaran
Journal:  medRxiv       Date:  2022-07-21
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.